MAPT and Alzheimer disease: Alzheimer‘s disease (AD) is a progressive neurodegenerative disorder, encompassing the deterioration of cognitive functions and behavioral changes, characterized by the aggregation of amyloid β-protein (Aβ) into fibrillar amyloid plaques in selected areas of the brain with the lipid-carrier protein apolipoprotein E (apoE), the microtubule associated protein tau, and the presynaptic protein α-synuclein [2,5–7].